P3 Health Partners (PIII) Competitors

P3 Health Partners logo
$2.19 -0.22 (-9.13%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$2.19 0.00 (0.00%)
As of 03:59 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

PIII vs. BDSX, LFMD, PARK, JYNT, and BTMD

Should you buy P3 Health Partners stock or one of its competitors? P3 Health Partners's main competitors and comparable companies include Biodesix (BDSX), LifeMD (LFMD), Park Dental Partners (PARK), Joint (JYNT), and biote (BTMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does P3 Health Partners compare to Biodesix?

P3 Health Partners (NASDAQ:PIII) and Biodesix (NASDAQ:BDSX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.

P3 Health Partners currently has a consensus target price of $13.67, suggesting a potential upside of 524.05%. Biodesix has a consensus target price of $34.20, suggesting a potential upside of 285.14%. Given P3 Health Partners' higher possible upside, equities research analysts plainly believe P3 Health Partners is more favorable than Biodesix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
P3 Health Partners
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Biodesix
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86

7.8% of P3 Health Partners shares are held by institutional investors. Comparatively, 21.0% of Biodesix shares are held by institutional investors. 10.9% of P3 Health Partners shares are held by company insiders. Comparatively, 23.2% of Biodesix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Biodesix had 18 more articles in the media than P3 Health Partners. MarketBeat recorded 20 mentions for Biodesix and 2 mentions for P3 Health Partners. Biodesix's average media sentiment score of 0.14 beat P3 Health Partners' score of -0.15 indicating that Biodesix is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
P3 Health Partners
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Biodesix
3 Very Positive mention(s)
4 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

P3 Health Partners has a net margin of -3.30% compared to Biodesix's net margin of -25.74%. P3 Health Partners' return on equity of 0.00% beat Biodesix's return on equity.

Company Net Margins Return on Equity Return on Assets
P3 Health Partners-3.30% N/A -9.38%
Biodesix -25.74%-442.34%-29.16%

Biodesix has lower revenue, but higher earnings than P3 Health Partners. Biodesix is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
P3 Health Partners$1.46B0.01-$147.95M-$23.26N/A
Biodesix$88.50M1.11-$35.26M-$2.76N/A

P3 Health Partners has a beta of 1.81, suggesting that its share price is 81% more volatile than the broader market. Comparatively, Biodesix has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market.

Summary

Biodesix beats P3 Health Partners on 10 of the 17 factors compared between the two stocks.

How does P3 Health Partners compare to LifeMD?

LifeMD (NASDAQ:LFMD) and P3 Health Partners (NASDAQ:PIII) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, valuation, risk and analyst recommendations.

In the previous week, LifeMD had 14 more articles in the media than P3 Health Partners. MarketBeat recorded 16 mentions for LifeMD and 2 mentions for P3 Health Partners. LifeMD's average media sentiment score of 0.06 beat P3 Health Partners' score of -0.15 indicating that LifeMD is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
LifeMD
1 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
4 Negative mention(s)
0 Very Negative mention(s)
Neutral
P3 Health Partners
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

LifeMD has a net margin of -0.25% compared to P3 Health Partners' net margin of -3.30%. P3 Health Partners' return on equity of 0.00% beat LifeMD's return on equity.

Company Net Margins Return on Equity Return on Assets
LifeMD-0.25% -188.63% -32.24%
P3 Health Partners -3.30%N/A -9.38%

LifeMD has a beta of 2.19, suggesting that its stock price is 119% more volatile than the broader market. Comparatively, P3 Health Partners has a beta of 1.81, suggesting that its stock price is 81% more volatile than the broader market.

LifeMD presently has a consensus price target of $7.14, indicating a potential upside of 297.93%. P3 Health Partners has a consensus price target of $13.67, indicating a potential upside of 524.05%. Given P3 Health Partners' higher probable upside, analysts plainly believe P3 Health Partners is more favorable than LifeMD.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LifeMD
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.70
P3 Health Partners
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

35.5% of LifeMD shares are held by institutional investors. Comparatively, 7.8% of P3 Health Partners shares are held by institutional investors. 17.2% of LifeMD shares are held by insiders. Comparatively, 10.9% of P3 Health Partners shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

LifeMD has higher earnings, but lower revenue than P3 Health Partners. LifeMD is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LifeMD$194.05M0.45$14.35M-$0.06N/A
P3 Health Partners$1.46B0.01-$147.95M-$23.26N/A

Summary

LifeMD beats P3 Health Partners on 11 of the 16 factors compared between the two stocks.

How does P3 Health Partners compare to Park Dental Partners?

P3 Health Partners (NASDAQ:PIII) and Park Dental Partners (NASDAQ:PARK) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, dividends and institutional ownership.

P3 Health Partners presently has a consensus target price of $13.67, indicating a potential upside of 524.05%. Park Dental Partners has a consensus target price of $28.50, indicating a potential upside of 47.21%. Given P3 Health Partners' higher possible upside, equities research analysts plainly believe P3 Health Partners is more favorable than Park Dental Partners.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
P3 Health Partners
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Park Dental Partners
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.50

7.8% of P3 Health Partners shares are owned by institutional investors. 10.9% of P3 Health Partners shares are owned by insiders. Comparatively, 10.6% of Park Dental Partners shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Park Dental Partners had 6 more articles in the media than P3 Health Partners. MarketBeat recorded 8 mentions for Park Dental Partners and 2 mentions for P3 Health Partners. Park Dental Partners' average media sentiment score of 0.45 beat P3 Health Partners' score of -0.15 indicating that Park Dental Partners is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
P3 Health Partners
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Park Dental Partners
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Park Dental Partners has a net margin of -1.21% compared to P3 Health Partners' net margin of -3.30%. Park Dental Partners' return on equity of 27.76% beat P3 Health Partners' return on equity.

Company Net Margins Return on Equity Return on Assets
P3 Health Partners-3.30% N/A -9.38%
Park Dental Partners -1.21%27.76%4.20%

Park Dental Partners has lower revenue, but higher earnings than P3 Health Partners. Park Dental Partners is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
P3 Health Partners$1.46B0.01-$147.95M-$23.26N/A
Park Dental Partners$244.49M0.44-$360K-$1.91N/A

Summary

Park Dental Partners beats P3 Health Partners on 11 of the 15 factors compared between the two stocks.

How does P3 Health Partners compare to Joint?

P3 Health Partners (NASDAQ:PIII) and Joint (NASDAQ:JYNT) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk.

In the previous week, Joint had 7 more articles in the media than P3 Health Partners. MarketBeat recorded 9 mentions for Joint and 2 mentions for P3 Health Partners. Joint's average media sentiment score of 1.05 beat P3 Health Partners' score of -0.15 indicating that Joint is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
P3 Health Partners
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Joint
4 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

7.8% of P3 Health Partners shares are owned by institutional investors. Comparatively, 76.9% of Joint shares are owned by institutional investors. 10.9% of P3 Health Partners shares are owned by company insiders. Comparatively, 30.2% of Joint shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Joint has a net margin of 4.81% compared to P3 Health Partners' net margin of -3.30%. Joint's return on equity of 22.11% beat P3 Health Partners' return on equity.

Company Net Margins Return on Equity Return on Assets
P3 Health Partners-3.30% N/A -9.38%
Joint 4.81%22.11%6.15%

Joint has lower revenue, but higher earnings than P3 Health Partners. P3 Health Partners is trading at a lower price-to-earnings ratio than Joint, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
P3 Health Partners$1.46B0.01-$147.95M-$23.26N/A
Joint$54.90M1.66$2.91M$0.2033.25

P3 Health Partners currently has a consensus price target of $13.67, indicating a potential upside of 524.05%. Joint has a consensus price target of $8.00, indicating a potential upside of 20.30%. Given P3 Health Partners' stronger consensus rating and higher probable upside, research analysts clearly believe P3 Health Partners is more favorable than Joint.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
P3 Health Partners
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Joint
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

P3 Health Partners has a beta of 1.81, indicating that its stock price is 81% more volatile than the broader market. Comparatively, Joint has a beta of 1.16, indicating that its stock price is 16% more volatile than the broader market.

Summary

Joint beats P3 Health Partners on 11 of the 16 factors compared between the two stocks.

How does P3 Health Partners compare to biote?

P3 Health Partners (NASDAQ:PIII) and biote (NASDAQ:BTMD) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

7.8% of P3 Health Partners shares are owned by institutional investors. Comparatively, 21.7% of biote shares are owned by institutional investors. 10.9% of P3 Health Partners shares are owned by company insiders. Comparatively, 32.4% of biote shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

biote has lower revenue, but higher earnings than P3 Health Partners. biote is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
P3 Health Partners$1.46B0.01-$147.95M-$23.26N/A
biote$192.22M0.18$27.05M-$0.10N/A

P3 Health Partners presently has a consensus target price of $13.67, suggesting a potential upside of 524.05%. biote has a consensus target price of $2.50, suggesting a potential upside of 152.53%. Given P3 Health Partners' higher possible upside, analysts plainly believe P3 Health Partners is more favorable than biote.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
P3 Health Partners
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
biote
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.50

In the previous week, P3 Health Partners and P3 Health Partners both had 2 articles in the media. biote's average media sentiment score of 0.60 beat P3 Health Partners' score of -0.15 indicating that biote is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
P3 Health Partners
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
biote
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

P3 Health Partners has a beta of 1.81, indicating that its stock price is 81% more volatile than the broader market. Comparatively, biote has a beta of 1.73, indicating that its stock price is 73% more volatile than the broader market.

biote has a net margin of -1.08% compared to P3 Health Partners' net margin of -3.30%. P3 Health Partners' return on equity of 0.00% beat biote's return on equity.

Company Net Margins Return on Equity Return on Assets
P3 Health Partners-3.30% N/A -9.38%
biote -1.08%-8.61%4.61%

Summary

biote beats P3 Health Partners on 10 of the 15 factors compared between the two stocks.

Get P3 Health Partners News Delivered to You Automatically

Sign up to receive the latest news and ratings for PIII and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PIII and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PIII vs. The Competition

MetricP3 Health PartnersHealthcare Providers & Services IndustryHealthcare SectorNASDAQ Exchange
Market Cap$17.50M$10.88B$7.83B$11.74B
Dividend YieldN/A2.54%2.47%4.47%
P/E Ratio-0.0936.2734.3128.41
Price / Sales0.012.108.495.70
Price / CashN/A22.8921.0121.90
Price / Book-0.213.574.453.72
Net Income-$147.95M$332.46M$3.52B$393.10M
7 Day Performance-16.09%-4.24%-5.94%-5.77%
1 Month Performance-47.10%-1.72%-4.59%-7.14%
1 Year Performance-65.78%19.25%-1.94%-7.47%

P3 Health Partners Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PIII
P3 Health Partners
1.6878 of 5 stars
$2.19
-9.1%
$13.67
+524.0%
-63.4%$17.50M$1.46BN/A320
BDSX
Biodesix
3.986 of 5 stars
$10.02
-3.1%
$34.20
+241.3%
+12.1%$114.65M$88.50MN/A334
LFMD
LifeMD
2.9364 of 5 stars
$1.74
-17.1%
$7.57
+335.1%
-62.1%$100.98M$194.05MN/A384
PARK
Park Dental Partners
3.8538 of 5 stars
$21.50
+2.4%
$28.50
+32.6%
N/A$99.86M$251.37M20.481,212
JYNT
Joint
4.461 of 5 stars
$6.83
+2.7%
$8.00
+17.1%
-19.0%$91.03M$54.90M28.91330

Related Companies and Tools


This page (NASDAQ:PIII) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners